Frequency, management, and resource use of adverse events (AEs) in nonmetastatic castrate-resistant prostate cancer (nmCRPC) patients receiving apalutamide or enzalutamide: A real-world study.

Shan Jiang,Della Varghese,Sreevalsa Appukkuttan,Shelby Corman,Nehemiah Kebede,Kajan Gnanasakthy,Cynthia Macahilig,A. Reginald Waldeck,Arif Hussain

Frequency, management, and resource use of adverse events (AEs) in nonmetastatic castrate-resistant prostate cancer (nmCRPC) patients receiving apalutamide or enzalutamide: A real-world study.

2021

Shan Jiang
Della Varghese
Sreevalsa Appukkuttan
Shelby Corman
Nehemiah Kebede
Kajan Gnanasakthy
Cynthia Macahilig
A. Reginald Waldeck
Arif Hussain

217Background: Second generation androgen receptor inhibitors (SGARIs), apalutamide (APA) and enzalutamide (ENZ) and darolutamide, are approved in the United States (US) for the treatment of nmCRPC...

Keywords:

Oncology
Androgen receptor
Darolutamide
Apalutamide
Castrate-resistant prostate cancer
resource use
Adverse effect
Internal medicine
Medicine
frequency management
Enzalutamide

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations